Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 104 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen

Se ha producido un error durante la generación de la página

. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 2019;75:diciembre. [Ref.ID 103213]
2. Cita con resumen
Anónimo. Troubles rétiniens d'origine médicamenteuse. Prescrire 2019;39:19-25. [Ref.ID 103005]
3.Enlace a cita original Cita con resumen
Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer. A randomized clinical trial. JAMA 2018;319:10 de julio. [Ref.ID 102791]
4. Cita con resumen
Anónimo. Anastrozole: syndromes du canal carpien. Prescrire 2016;36:426. [Ref.ID 100544]
5. Cita con resumen
Anónimo. Atteintes tendineuses d'origine médicamenteuse. Prescrire 2016;36:265-8. [Ref.ID 100532]
6.Enlace a cita originalTiene citas relacionadas
Mayer EL, Burstein HJ. Postmenopausal breast cancer: a best endocrine strategy?. Lancet 2015;386:1317-9. [Ref.ID 99617]
7. Cita con resumen
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF, Austrian Breast, and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015;386:433-43. [Ref.ID 99481]
8. Cita con resumen
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341-52. [Ref.ID 99276]
9.Tiene citas relacionadas
Hugo HS. Hormone theray in premenopausal women with early-stage breast cancer. N Engl J Med 2014;371:175-6. [Ref.ID 97810]
10.Tiene citas relacionadas Cita con resumen
Pagani O, Regan MM, Walley BA, Fleming GF, Collecni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Steams V, Bonnefoi HR, Martino S, Geyer Jr CE, Pinotti G, Puglisi F, Crivellari D, Rushtaller T, Winer EP, Rabaglio-Poretti M, Malbach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, for the TEXT and SOFT Investigators and the International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107-18. [Ref.ID 97807]
11.Tiene citas relacionadas
Cameron DA. Breast cancer chemoprevention: little progress in practice?. Lancet 2014;383:1018-20. [Ref.ID 97307]
12.Tiene citas relacionadas Cita con resumen
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders Ch, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, on behalf of the IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014;383:1041-8. [Ref.ID 97306]
13. Cita con resumen
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012;367:435-44. [Ref.ID 93581]
15.Tiene citas relacionadas Cita con resumen
Anónimo. Tamoxifen and CYP 2D6 inhibitors: caution. Prescrire Int 2011;20:182-4. [Ref.ID 91095]
16. Cita con resumen
Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Waclawski-Wende J, Mctiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farner P, Gelmon KA, Tu D, Richardson H, for the NCIC CTG MAP-3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91. [Ref.ID 90936]
17.Tiene citas relacionadas Cita con resumen
Anónimo. Tamoxifène et inhibiteurs de l'isoenzyme CYP 2D6: prudence. Prescrire 2011;31:190-2. [Ref.ID 90306]
18.Tiene citas relacionadas
Munster PN, Carpenter JT. Estradiol in breast cancer treatment. Reviving the past. JAMA 2009;302:797-8. [Ref.ID 86577]
19.Tiene citas relacionadas Cita con resumen
Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer. A phase 2 randomized study. JAMA 2009;302:774-80. [Ref.ID 86572]
20. Cita con resumen
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, for the ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91. [Ref.ID 85243]
Seleccionar todas
 
 1 a 20 de 104 siguiente >>